GlassScriptPhysician profile
Melissa M Beach
NPI 1720062151
$598.70
in general payments reported to CMS, 2019-2025
14 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $214 · 2024: $280 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $106.16 | 2023-2024 | Xarelto |
| Neurelis, INC. | $76.36 | 2023-2025 | Valtoco |
| Merck Sharp & Dohme LLC | $75.72 | 2024 | Zerbaxa, Dificid, Recarbrio |
| Novartis Pharmaceuticals Corporation | $66.05 | 2023-2024 | |
| Smith+Nephew, INC. | $48.99 | 2024 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.87 | 2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.34 | 2024-2025 | Lifevest |
| Boston Scientific Corporation | $28.53 | 2025 | General - Thrombectomy |
| Jazz Pharmaceuticals INC. | $25.33 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $23.63 | 2025 | Eliquis |
| Viatris Specialty LLC | $22.84 | 2025 | Yupelri |
| Csl Behring | $18.37 | 2023 | Kcentra |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2024 | Farxiga |
| Gilead Sciences, INC. | $13.46 | 2023 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.